CORMEDIX ($CRMD) posted quarterly earnings results for Q1 2026 on Thursday, May 14th. The company reported earnings of $0.43 per share, beating estimates of $0.37 by $0.06. The company also reported revenue of $127,430,000, beating estimates of $107,117,340 by $20,312,660.
You can see Quiver Quantitative's $CRMD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CORMEDIX Insider Trading Activity
CORMEDIX insiders have traded $CRMD stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $CRMD stock by insiders over the last 6 months:
- JANET DILLIONE has made 0 purchases and 5 sales selling 147,000 shares for an estimated $1,547,555.
- STEVEN W LEFKOWITZ sold 40,000 shares for an estimated $475,200
- JOSEPH TODISCO (Chief Executive Officer) sold 30,000 shares for an estimated $360,000
- ALAN W DUNTON sold 20,000 shares for an estimated $260,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
CORMEDIX Hedge Fund Activity
We have seen 105 institutional investors add shares of CORMEDIX stock to their portfolio, and 102 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 4,774,076 shares (+954.8%) to their portfolio in Q4 2025, for an estimated $55,522,503
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 2,215,889 shares (-66.7%) from their portfolio in Q4 2025, for an estimated $25,770,789
- MARSHALL WACE, LLP removed 1,507,232 shares (-43.4%) from their portfolio in Q4 2025, for an estimated $17,529,108
- CITADEL ADVISORS LLC removed 1,396,937 shares (-81.4%) from their portfolio in Q4 2025, for an estimated $16,246,377
- UBS GROUP AG added 902,210 shares (+141.8%) to their portfolio in Q1 2026, for an estimated $6,126,005
- QUBE RESEARCH & TECHNOLOGIES LTD removed 637,497 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $7,414,090
- JUMP FINANCIAL, LLC removed 637,293 shares (-82.3%) from their portfolio in Q4 2025, for an estimated $7,411,717
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
CORMEDIX Analyst Ratings
Wall Street analysts have issued reports on $CRMD in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 02/11/2026
- HC Wainwright & Co. issued a "Buy" rating on 01/23/2026
- Needham issued a "Buy" rating on 01/08/2026
To track analyst ratings and price targets for CORMEDIX, check out Quiver Quantitative's $CRMD forecast page.
CORMEDIX Price Targets
Multiple analysts have issued price targets for $CRMD recently. We have seen 6 analysts offer price targets for $CRMD in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Leonid Timashev from RBC Capital set a target price of $14.0 on 04/28/2026
- Jason N. Butler from Citizens set a target price of $19.0 on 04/28/2026
- Roanna Ruiz from Leerink Partners set a target price of $14.0 on 04/28/2026
- Jason Kolbert from D. Boral Capital set a target price of $14.0 on 04/27/2026
- Serge Belanger from Needham set a target price of $15.0 on 04/27/2026
- Brandon Folkes from HC Wainwright & Co. set a target price of $13.0 on 01/23/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
